Verona Pharma Initiates Phase 3 Clinical Trials with Nebulized Ensifentrine for the Maintenance Treatment of COPD
Verona Pharma plc (VRP.L) Phase 3 Clinical Trials with Nebulized Ensifentrine
OKYO PHARMA LIMITED (OKYO.L) Grant of options – Director dealings
OKYO Pharma Limited (LSE: OKYO) (“OKYO” or the “Company”), the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases
OKYO PHARMA LIMITED (OKYO.L) Dr. Napoleone Ferrara to Serve on Its Scientific Advisory Board
OKYO , the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce
OKYO PHARMA LIMITED (OKYO.L) CLNs to raise £1.4m, intends to list: NASDAQ
Issue of additional convertible loan notes to raise £1,437,104 and intention to seek dual listing on NASDAQ
Verona Pharma plc (VRP.L) $200 Million in Oversubscribed Private Placement and Subscription
Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces it has raised approximately $200 million (£159 million*).
Genedrive PLC (GDR.L) Investor presentation
genedrive plc (LSE: GDR), the near-patient molecular diagnostics company, is pleased to announce that David Budd, Chief Executive Officer, will be presenting at an investor webinar being hosted jointly by
